Age and comorbidity identified poor prognosis in elderly patients receiving esophageal chemoradiotherapy
Patients aged ≥75 years with CIRS-G ≥7 had median overall survival of 16 months after definitive chemoradiotherapy.
Tag
chemoradiotherapy
Induction TPF did not improve three-year PFS over adjuvant PF in locally advanced NPC
Three-year PFS was 79.0% with induction TPF versus 74.5% with adjuvant PF, with substantially different toxicity profiles.
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
Iridium-192 boost improved progression-free survival in unresectable hilar cholangiocarcinoma
An iridium-192 boost increased median progression-free survival from 8.6 to 11.2 months, without a significant overall-survival improvement.
Twice-daily radiotherapy was associated with longer survival in younger limited-stage small cell lung cancer
Among patients under 70, twice-daily chemoradiotherapy was associated with 36.0 versus 22.2 months median survival, without higher acute toxicity.
Carboplatin-paclitaxel showed comparable outcomes in cisplatin-ineligible head and neck cancer
Retrospective outcomes with carboplatin-paclitaxel were not significantly different from cisplatin, supporting its use when cisplatin is contraindicated.
Escalating esophageal chemoradiotherapy from 50.4 to 60 Gy provided no benefit
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.
Bladder dose escalation reduced invasive recurrence without increasing toxicity
Two-year invasive recurrence fell from 27.5% to 5.5% with dose escalation, without higher grade 2 or greater toxicity.
Most PLATO quality-of-life deficits recovered by six months, but advanced disease remained burdensome
Most treatment-related deficits improved by six months, although bowel and sexual problems persisted in several standard-dose and locally advanced groups.
Multimodal models appear most promising for predicting rectal cancer pathological complete response
No individual clinical, imaging, blood, or molecular marker reliably predicted pathological complete response, while integrated multimodal models showed greater potential.
Postoperative radiotherapy did not improve survival beyond chemotherapy in pT3N0M0 oesophageal cancer
Adding postoperative radiotherapy to chemotherapy did not significantly improve survival after R0 resection of pT3N0M0 oesophageal squamous cell carcinoma.
Dose-escalated chemoradiotherapy improved nine-year survival in locally advanced rectal cancer
A 56 Gy simultaneous integrated boost improved nine-year survival and disease control compared with standard 50 Gy chemoradiotherapy.
Review links chemoresistance and radioresistance through shared adaptive programmes
Chemotherapy and radiotherapy resistance may converge on shared DNA-repair, redox, metabolic, stemness and microenvironmental adaptations.
NEOTRAC shortened treatment duration without improving pCR in HER2-positive inoperable breast cancer
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
Perioperative immunotherapy with chemoradiation showed encouraging response in resectable gastric and gastroesophageal junction cancer
A single-arm phase 1/2 trial reported a 39.1% pathologic complete response rate among resected patients, with grade 4 toxicities in 10%.